SUMOylation inhibition overcomes dexamethasone resistance in multiple myeloma

SUMOylation, a posttranslational modification, regulates proteins by covalent attachment of small ubiquitin-like modifier (SUMO) proteins to a lysine (Lys) residue on target proteins. Here we use TAK-981, a selective SUMO-activating enzyme (SAE) inhibitor, to inhibit global SUMOylation in glucocorticoid sensitive and resistant multiple myeloma cell lines. Human multiple myeloma cell lines MM1.S (glucocorticoid sensitive) and MM1.R (glucocorticoid resistant) were treated with 0.1μM TAK-981, or 1μM Dexamethasone or combo (0.1μM TAK-981 and 1μM Dexamethasone) for 48 h in duplicate, total RNAs were extracted and sequenced.